https://orcid.org/0000-0003-0943-4422
References
- Commandeur AE, Styer AK, Teixeira JM. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 2015 Sep-Oct;21(5):593–615. doi: 10.1093/humupd/dmv030
- Bulun SE, Longo DL. Uterine fibroids. N Engl J Med. 2013 Oct 3;369(14):1344–1355.
- Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14(2):247–250. doi: 10.1097/01.EDE.0000054360.61254.27
- Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012 Mar;206(3):211 e1–9. doi: 10.1016/j.ajog.2011.12.002
- Zimmermann A, Bernuit D, Gerlinger C, et al. Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women. BMC Women’s Health. 2012;12(1):1–11. doi: 10.1186/1472-6874-12-6
- Eltoukhi HM, Modi MN, Weston M, et al. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. 2014 Mar;210(3):194–199. doi: 10.1016/j.ajog.2013.08.008
- George JW, Fan H, Johnson B, et al. Integrated epigenome, exome, and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. Cell Rep. 2019 Dec 17;29(12):4069–4085 e6. doi: 10.1016/j.celrep.2019.11.077
- Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocrine Reviews. 2013;34(1):130–162. doi: 10.1210/er.2012-1043
- McWilliams MM, Chennathukuzhi VM. Recent advances in uterine fibroid etiology. Semin Reprod Med. 2017 Mar;35(2):181–189. doi: 10.1055/s-0037-1599090
- Khan AT, Shehmar M, Gupta JK. Uterine fibroids: current perspectives. Int J Women's Health. 2014;6:95–114. doi: 10.2147/IJWH.S51083
- Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol. 2002;186(3):409–415. doi: 10.1067/mob.2002.121725
- De La Cruz MS, Buchanan EM. Uterine fibroids: diagnosis and treatment. Am Fam Physician. 2017 Jan 15;95(2):100–107.
- Saleh FL, Taylor HS. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. F S Rep. 2023 Jun;4(2 Suppl):83–87. doi: 10.1016/j.xfre.2023.01.008
- Deng L, Wu T, Chen XY, et al. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2012 Oct 17;10:Cd005287.
- Islam MS, Afrin S, Jones SI, et al. Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev. 2020 Oct 1;41(5): doi: 10.1210/endrev/bnaa012
- Ekine AA, Lawani LO, Iyoke CA, et al. Review of the clinical presentation of uterine fibroid and the effect of therapeutic intervention on fertility. Am J Clin Med Res. 2015;3(1):9–13.
- Neis KJ, Zubke W, Fehr M, et al. Hysterectomy for Benign uterine disease. Dtsch Arztebl Int. 2016 Apr 8;113(14):242–249. doi: 10.3238/arztebl.2016.0242